Structure, Function and Conformational Dynamics of the Ste14p Methyltransferase

Ste14p 甲基转移酶的结构、功能和构象动力学

基本信息

  • 批准号:
    8675864
  • 负责人:
  • 金额:
    $ 27.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-01 至 2018-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal focuses on an in-depth analysis of the structure, function and dynamics of the Ste14p isoprenylcysteine carboxyl methyltransferase (Icmt) from S. cerevisiae, the integral membrane enzyme that is responsible for the posttranslational ?-carboxyl methyl esterification of a large number of cellular proteins that terminate in a C-terminal CaaX motif. CaaX proteins undergo three sequential post-translational modifications: isoprenylation of the cysteine residue, endoproteolysis of the -aaX residues, and methylation of the isoprenylated cysteine by Icmt. Methylation is critical for the proper localization of the CaaX protein K-Ras and may be essential for oncogenic transformation; thus, Icmt may prove to be an excellent chemotherapeutic target. To date, few molecular details are known about the mechanism of Ste14p except that it must accommodate chemically diverse methyl donor and acceptor molecules: the hydrophilic co-factor S- adenosylmethionine (SAM) and a lipophilic isoprenylated protein substrate, respectively. Our long term goal is to understand in mechanistic detail how such an enzyme mediates catalysis at the membrane/cytosol interface. Specifically, our goals in the current proposal are to understand the structure-function relationships of co-factor and substrate recognition by the Icmt enzyme and to elucidate the structural dynamics of the co- factor binding/catalytic loop of the enzyme. As mammalian Icmts have proven intractable to functional purification, we will use Ste14p, as our model enzyme. We have overexpressed, purified and functionally reconstituted milligram quantities of both wild-type and a cysteine-less variant of Ste14p in yeast. We have also generated and characterized a large library of site- directed mutants in conserved residues of His-Ste14p. Using these tools, we are now poised to identify key residues that comprise the binding sites in Ste14p for isoprenylated substrates. We are also set up to identify important residues responsible for binding of the co-factor SAM and to reveal conformational changes that occur in the enzyme upon co-factor and/or lipidated substrate binding by SDSL EPR, guided by a structural homology model of the C-terminal catalytic half of Ste14p that is based on the crystal structure of a bacterial Icmt ortholog. Together, these studies will provide key insights into the nature of substrate and co-factor recognition by Ste14p that will give a better understanding of its mechanism of action. Given the structural, functional and sequence similarities between Ste14p and other Icmts, study of the yeast enzyme should offer general mechanistic insight into the function of other members of this class of enzymes which ultimately may provide the basis for the rational design of anti-cancer drugs targeting human Icmt.
描述(由申请人提供):本提案侧重于深入分析来自S.酿酒酵母,膜酶的组成部分,是负责翻译后?大量终止于C-末端CaaX基序的细胞蛋白质的羧甲基酯化。CaaX蛋白经历三个连续的翻译后修饰:异戊二烯化的半胱氨酸残基,内切蛋白水解的-aaX残基,和甲基化的异戊二烯化的半胱氨酸的ICMT。甲基化对于CaaX蛋白K-Ras的适当定位是至关重要的,并且对于致癌转化可能是必不可少的;因此,Icmt可能被证明是极好的化疗靶点。 到目前为止,很少有分子的细节是已知的机制Ste 14 p,除了它必须适应化学上不同的甲基供体和受体分子:亲水性辅因子S-腺苷甲硫氨酸(SAM)和亲脂性异戊二烯化蛋白质底物,分别。我们的长期目标是详细了解这种酶如何在膜/胞质界面介导催化作用。具体而言,我们的目标是在目前的建议是了解辅因子和底物识别的ICMT酶的结构-功能关系,并阐明辅因子结合/催化环的酶的结构动力学。由于哺乳动物ICMTS已被证明难以进行功能纯化,我们将使用Ste 14 p作为我们的模型酶。 我们已经过表达,纯化和功能重建毫克量的野生型和半胱氨酸的变体Ste 14 p在酵母中。我们还产生并表征了His-Ste 14 p保守残基中的定点突变体的大文库。使用这些工具,我们现在准备确定关键的残基,包括在Ste 14 p的异戊二烯化底物的结合位点。我们还建立了确定重要的残基负责的辅因子SAM的结合,并揭示构象变化时,发生在酶的辅因子和/或脂化底物结合SDSL EPR,由结构同源性模型的C-末端催化的一半的Ste 14 p是基于细菌Icmt直系同源物的晶体结构的指导。 总之,这些研究将提供关键的洞察底物和辅因子识别的性质,通过STE 14 p,将使其作用机制有一个更好的理解。考虑到Ste 14 p和其他Icmt之间的结构,功能和序列相似性,酵母酶的研究应该提供一般的机制洞察到这类酶的其他成员的功能,最终可能提供的基础上,合理设计的抗癌药物靶向人类Icmt。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTINE A HRYCYNA其他文献

CHRISTINE A HRYCYNA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTINE A HRYCYNA', 18)}}的其他基金

FASEB SRC on Protein Lipidation, Signaling and Membrane Domains.
FASEB SRC 关于蛋白质脂化、信号传导和膜结构域。
  • 批准号:
    8977960
  • 财政年份:
    2015
  • 资助金额:
    $ 27.92万
  • 项目类别:
Structure, Function and Conformational Dynamics of the Ste14p Methyltransferase
Ste14p 甲基转移酶的结构、功能和构象动力学
  • 批准号:
    8483309
  • 财政年份:
    2013
  • 资助金额:
    $ 27.92万
  • 项目类别:
Structure, Function and Conformational Dynamics of the Ste14p Methyltransferase
Ste14p 甲基转移酶的结构、功能和构象动力学
  • 批准号:
    9040994
  • 财政年份:
    2013
  • 资助金额:
    $ 27.92万
  • 项目类别:
FASEB SRC on Protein Lipidation, Signaling and Membrane Domains
FASEB SRC 关于蛋白质脂化、信号传导和膜结构域
  • 批准号:
    8203842
  • 财政年份:
    2011
  • 资助金额:
    $ 27.92万
  • 项目类别:
Modulating P-glycoprotein to Enhance Neurodegenerative Drug Penetration of Brain
调节 P-糖蛋白增强神经退行性药物在大脑中的渗透
  • 批准号:
    7489886
  • 财政年份:
    2007
  • 资助金额:
    $ 27.92万
  • 项目类别:
Modulating P-glycoprotein to Enhance Neurodegenerative Drug Penetration of Brain
调节 P-糖蛋白增强神经退行性药物在大脑中的渗透
  • 批准号:
    7329774
  • 财政年份:
    2007
  • 资助金额:
    $ 27.92万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 27.92万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 27.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 27.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 27.92万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 27.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了